Shots:

• Zydus’ ZyCoV-D has completed the preclinical studies and has received DCGI approval to initiate P-I/II human clinical trials in India. In its preclinical study- the vaccine demonstrated that it is capable to neutralize the wild type virus in the virus neutralization assay
• In its toxicology studies- the vaccine is found to be safe- well-tolerated and immunogenic
• Zydus has manufactured clinical GMP batches of the vaccine with the expected initiation of clinical trials in Jul’2020 across multiple sites in India in over 1000 subjects. Additionally- the company will ramp up the production capacities of ZyCoV-D at multiple sites to meet the global demand

Click here to read full press release/ article | Ref: Zydus | Image: Arab News